These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 15919498)
1. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus? Gelens MA; Christiaans MH; v Hooff JP Transplant Proc; 2005 May; 37(4):1900-1. PubMed ID: 15919498 [TBL] [Abstract][Full Text] [Related]
2. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605 [TBL] [Abstract][Full Text] [Related]
3. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. Pohanka E; Margreiter R; Sparacino V; Sperschneider H; Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490 [TBL] [Abstract][Full Text] [Related]
4. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. Marcén R; Chahin J; Alarcón A; Bravo J Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957 [TBL] [Abstract][Full Text] [Related]
10. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation]. Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128 [TBL] [Abstract][Full Text] [Related]
11. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin. Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021 [TBL] [Abstract][Full Text] [Related]
12. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters. Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364 [TBL] [Abstract][Full Text] [Related]
13. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154 [TBL] [Abstract][Full Text] [Related]
14. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540 [TBL] [Abstract][Full Text] [Related]
15. The influence of calcineurin inhibitors on pulse wave velocity in renal transplant recipients. Strózecki P; Adamowicz A; Włodarczyk Z; Manitius J Ren Fail; 2007; 29(6):679-84. PubMed ID: 17763162 [TBL] [Abstract][Full Text] [Related]
16. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076 [TBL] [Abstract][Full Text] [Related]
17. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. Zawiasa A; Szklarek-Kubicka M; Fijałkowska-Morawska J; Nowak D; Rysz J; Mamełka B; Nowicki M Transplant Proc; 2009; 41(1):188-91. PubMed ID: 19249511 [TBL] [Abstract][Full Text] [Related]
18. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. Woodside KJ; Nichols SD; Hunter GC; Gugliuzza KK; Daller JA Transplant Proc; 2005 May; 37(4):1877-9. PubMed ID: 15919491 [TBL] [Abstract][Full Text] [Related]
19. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation. Wang CH; Chou NK; Ko WJ; Chi NH; Tsao CI; Wang SS Transplant Proc; 2008 Oct; 40(8):2600-2. PubMed ID: 18929812 [TBL] [Abstract][Full Text] [Related]
20. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. Beckebaum S; Klein C; Varghese J; Sotiropoulos GC; Saner F; Schmitz K; Gerken G; Paul A; Cicinnati VR Aliment Pharmacol Ther; 2009 Oct; 30(8):834-42. PubMed ID: 19624550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]